Biodexa Pharmaceuticals PLC ADR Ratio Change

Biodexa Pharmaceuticals PLC announced a change in its American Depositary Receipts (ADR) ratio, effective around April 6, 2026. The new ratio will be one ADR representing 500,000 ordinary shares, changed from the previous ratio of one ADR representing 100,000 ordinary shares. This change is equivalent to a one-for-five reverse ADR split and aims to comply with the Nasdaq minimum bid price requirement of $1.00 per share. ADR holders will be required to surrender their existing ADRs for new ones on a mandatory basis. Fractional ADRs will be handled by selling them and distributing the net proceeds. The company's ordinary shares will not be affected by this ratio change. Biodexa cautions that there is no guarantee this change will achieve Nasdaq compliance.